Ashley Nichols
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashley Nichols has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abraham Shim
Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, USA
33 shared publications - Alexandra Dananberg
Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York
33 shared publications - Eléonore Toufektchan
Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York
33 shared publications - James H. Hickling
The Rockefeller University
33 shared publications - John Maciejowski
Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA
33 shared publications - Josefine Striepen
Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, USA
33 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
TREX1 promotes tumor growth, but not in vitro cell proliferation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
TREX1 promotes tumor growth, but not in vitro cell proliferation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Individual growth curves of tumors transplanted in Rag1 KO and NU/J hosts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Individual growth curves of tumors transplanted in Rag1 KO and NU/J hosts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
CGAS-STING-dependent TREX1 upregulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
CGAS-STING-dependent TREX1 upregulation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Generation of KO cell lines and extracellular cGAMP measurements.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Generation of KO cell lines and extracellular cGAMP measurements.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Individual growth curves of tumors treated with anti-PD-1 and isotype controls.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Individual growth curves of tumors treated with anti-PD-1 and isotype controls.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Frequency of micronucleation and micronuclear envelope rupture are similar across KO models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Frequency of micronucleation and micronuclear envelope rupture are similar across KO models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Characterization of intratumoral immune cell infiltration.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Characterization of intratumoral immune cell infiltration.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Paclitaxel treatment increases micronucleation, cGAS activity, and TREX1 expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Paclitaxel treatment increases micronucleation, cGAS activity, and TREX1 expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Characterization of Irf3 KOs and individual growth curves of tumors following disruption of IFN signaling.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
Characterization of Irf3 KOs and individual growth curves of tumors following disruption of IFN signaling.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 9 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
IFN and gene expression analysis after treatment with paclitaxel, HT-DNA, and poly(I:C).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 9 from Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN
IFN and gene expression analysis after treatment with paclitaxel, HT-DNA, and poly(I:C).